| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Maverick Capital · Lee Ainslie | $2.2M | 0.02% | 33.04K | +159% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Kevin Hern OK01 | 1 | −$8.0K | Sold Aug 5, 26 | |
| Alan Armstrong Sen. OK | 1 | +$8.0K | Bought Mar 30, 26 | |
| Josh Gottheimer NJ05 | 1 | −$8.0K | Sold Mar 12, 26 | |
| Julie Johnson TX32 | 1 | −$8.0K | Sold Mar 3, 25 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| Aug 5, 26 | Kevin Hern OK01 | Self | Sell | $1,001 - $15,000 | Sep 1, 26 (27d) | |
| Mar 30, 26 | Alan Armstrong Sen. OK | Self | Buy | $1,001 - $15,000 | Jul 21, 26 (113d) | Report |
| Mar 12, 26 | Josh Gottheimer NJ05 | Joint | Sell | $1,001 - $15,000 | Apr 8, 26 (27d) | |
| Mar 3, 25 | Julie Johnson TX32 | Joint | Sell | $1,001 - $15,000 | Apr 14, 25 (42d) |
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for ALC.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.8 | 7.7 | -13.6 | -0.6 | -11.5 | 1.2 | 2.7 | 4.5 | -10.1 | -3.1 | −20.4% | ||
| 2025 | 7.3 | 1.5 | 2.6 | 2.8 | -12.0 | 2.7 | -0.8 | -8.8 | -6.6 | -0.8 | 7.3 | -0.6 | −7.2% |
| 2024 | -3.9 | 12.6 | -1.5 | -6.9 | 14.9 | -0.1 | 5.5 | 3.9 | 2.4 | -8.1 | -3.4 | -4.5 | +8.7% |
| 2023 | 9.7 | -9.3 | 3.4 | 2.8 | 6.8 | 6.1 | 3.4 | -2.3 | -7.1 | -7.4 | 6.0 | 3.3 | +14.0% |
| 2022 | -11.9 | 0.3 | 3.0 | -10.2 | 4.9 | -6.5 | 11.7 | -15.9 | -11.4 | 4.3 | 13.5 | -0.5 | −21.3% |
| 2021 | 8.7 | -4.6 | 2.6 | 7.5 | -7.6 | 0.8 | 3.6 | 13.3 | -2.4 | 3.6 | -6.0 | 11.1 | +32.0% |
| 2020 | 4.2 | 4.0 | -17.1 | 3.9 | 20.3 | -9.8 | 4.6 | -4.4 | -0.7 | -0.2 | 13.0 | 2.7 | +16.6% |
| 2019 | -0.0 | 6.7 | -5.3 | 3.8 | -4.4 | 1.7 | -6.7 | 2.3 | −2.8% |
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Buy / hold / sell counts